Seeking Alpha

Seeking Alpha Portfolio App for iPad

3,809 people get SRPT articles and Market Currents by email alert.

Get email alerts on SRPT »

SRPT

Sarepta Therapeutics, Inc.

5/22/2013, 5:50 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 9, 8:27 AM More on Sarepta Therapeutics' (SRPT) Q1: Nothing particularly groundbreaking regarding eteplirsen in the PR. The company says it is "encouraged" by its correspondence with the FDA and is "finalizing" its response to requests for further information (I, II). A $6.7M decrease in government contract revenue is blamed for the higher (Y/Y) operating loss. Operating expenses were higher as the company expands its Duchenne muscular dystrophy program. Shares +1.24% premarket. 2 Comments [Earnings, On the Move, Healthcare]
Thursday, May 9, 7:01 AM Sarepta Therapeutics (SRPT): Q1 EPS of -$0.41 beats by $0.21. Revenue of $4.5M misses by $1.35M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, May 9, 12:05 AM Notable earnings before Thursday’s open: AES, AGU, ALR, AM, AMRC, APA, BAM, BCE, CBB, CNSL, CTB, CVC, DF, DISH, DNDN, GLP, GTIV, IRC, KEM, KIOR, MEA, NPSP, OWW, PCP, SNE, SNSS, SPH, SRPT, TK, TNK, VICL, VNDA, WAC, WFR, WIN, WWAV, XRAY Comment! [Earnings]
Wednesday, May 8, 5:30 PM Notable earnings before Thursday’s open: AES, AGU, ALR, AM, AMRC, APA, BAM, BCE, CBB, CNSL, CTB, CVC, DF, DISH, DNDN, GLP, GTIV, IRC, KEM, KIOR, MEA, NPSP, OWW, PCP, SNE, SNSS, SPH, SRPT, TK, TNK, VICL, VNDA, WAC, WFR, WIN, WWAV, XRAY Comment! [Earnings]
Wednesday, April 24, 12:42 PM The latest chatter on Sarepta's (SRPT -3.7%) etiplirsen: Edison Investment Research's Jason Zhang notes that the FDA is now "squarely in the middle of the bull and bear scenarios" for SRPT and says the regulator will make a decision on the company's NDA application for etiplirsen "likely before the end of the year." By contrast, Leerink Swann said last week the company may "need to run a Phase III trial in 2014." 2 Comments [Healthcare, On the Move]
Monday, April 22, 8:28 AM Sarepta Therapeutics (SRPT) gets a 3% premarket lift from an initiation at Needham (Buy). Analyst Chad Messer is positive on eteplirsen and says he believes "the market reacted inappropriately to last week's regulatory update." The FDA requested "additional information" last Monday in order to evaluate an Accelerated Approval application, news the market did not like. (See also: Leerink Swann uncertain about SRPT) 1 Comment [On the Move, Healthcare]
Tuesday, April 16, 12:59 PM Midday top 10 gainers: UNXL +16%. CNIT +15%. ANEN +15%. CHCI +14%. SYNM +13%. PNFP +12%. EVC +12%. ENPH +11%. NCQ +11%. ACOR +11%.
Midday top 10 losers: JAXB -33%. KEYN -15%. SRPT -12%. CPGI -10%. GENE -10%. TRIT -9%. CCXI -9%. MAGS -9%. ADAT -8%. GAI -8%. Comment! [On the Move]
Tuesday, April 16, 9:10 AM Premarket gainers: NWBO +9%. GFI +7%. BCRX +7%. HK +7%. AU +7%. NG +6%. AUQ +6%. SAND +6%. GOLD +5%. KGC +5%.
Losers: LDK -16%. SRPT -11%. 1 Comment [On the Move]
Tuesday, April 16, 9:03 AM A downgrade from Leerink Swann to Market Perform from Outperform adds to Sarepta Therapeutics' (SRPT) problems. The FDA's request has "prolonged uncertainty" and the need to run a Phase III trial preapproval could give GlaxoSmithKline (GSK) and Prosensa's drisapersen treatment a first-to-market advantage. SRPT shares now -10.17% premarket. 2 Comments [Healthcare, On the Move]
Tuesday, April 16, 8:17 AM Investors appear skeptical about the FDA's request for additional information from Sarepta Therapeutics (SRPT) regarding the company's Duchenne muscular dystrophy drug. CEO Chris Garabedian says he does not anticipate "an impact on SRPT's ongoing activities" from the FDA's request or from the delay it occasioned in the accelerated approval submission process. Nonetheless, the shares are -6.22% premarket. Comment! [Healthcare, On the Move]
Monday, April 15, 5:47 PM After-hours top gainers, as of 5:15 p.m.: CNW +6%. SPR +6%. SWC +5%. RES +4.5%. RBC +4.4%.
After-hours top losers: SRPT -12%. CLI -7%. HCA -5%. EGOV -4.0%. KDN -3.2%. Comment! [On the Move]
Monday, April 15, 4:22 PM Sarepta Therapeutics (SRPT) says the FDA is considering accelerated approval of eteplirsen for the treatment of Duchenne muscular dystrophy. The agency has requested SRPT provide additional information from its existing dataset to help facilitate a decision on its acceptability for a New Drug Application filing under the Subpart H Accelerated Approval regulatory pathway. Shares -0.4% AH. 1 Comment [Healthcare, On the Move]
Monday, April 15, 3:59 PM A brief move into positive territory by Sarepta Therapeutics (SRPT -2.7%) midday might have been the result of comments from Wedbush (Outperform) analyst Christopher Marai who says progress on FDA approval for the company's Duchenne muscular dystrophy drug Eteplirsen is "encouraging." 2 Comments [Healthcare]
Sunday, April 14, 8:25 AM The reconstitution of the Russell indexes coming up in June, Credit Suisse aims to anticipate who's in and who's out. The rules-based approach of the Russell 2000 has allowed arbitragers to profit each summer by front-running the moves, making the Russell 2000 ETF (IWM) a poorer play for small cap fans than IJR . Expected among the top 25 adds are ARCP, SRPT, PBYI, ACAD, and WSTC. Among the top 25 deletes: CPST, FCEL, CHKE, OMER, and EML. Comment! [Quick Ideas]
Friday, April 5, 2:22 PM Piper Jaffray weighs in on Sarepta's (SRPT +5.3%) earlier data update on its Phase IIb study of on eteplirsen saying its very encouraged as there are no treatment options for DMD. The primary near-term value driver in the stock is SRPT's decision to file for accelerated approval later this month. Piper projects a 50/50 chance it will be able to file on existing data. Comment! [Healthcare, On the Move]
Friday, April 5, 11:02 AM Sarepta Therapeutics (SRPT +5.5%) racks up solid gains today after the therapeutic drug developer announced positive updated data from its Phase IIb study of eteplirsen in patients with Duchenne muscular dystrophy. Results at 74 weeks showed a continued stabilization of walking ability in eteplirsen-treated patients on a 6-minute walk test. Comment! [Healthcare, On the Move]